Clinical Trial Update: A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, pharmacokinetics, pharmacodynamics, and immunogenicity of N-Rephasin SAL200 in healthy male volunteers; completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Volunteers
• Methicillin-resistant Staphylococcus Aureus Infection
• Methicillin-sensitive Staphylococcus Aureus Infection

Drugs mentioned

• N-Rephasin SAL200 (N-Rephasin SAL200)

Snippet

Sponsor: Intron Biotechnology, Inc. | Conditions: Healthy Volunteers, Anti-Bacterial Agents | Phase 1 | Status: COMPLETED | Results posted: 2021-10-08